ClinicalTrials.gov
ClinicalTrials.gov Menu

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (AML-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00091234
Recruitment Status : Unknown
Verified July 2012 by European Organisation for Research and Treatment of Cancer - EORTC.
Recruitment status was:  Recruiting
First Posted : September 9, 2004
Last Update Posted : July 24, 2012
Sponsor:
Collaborator:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2013
  Study Completion Date : No date given
Publications of Results:
Amadori S, Suciu S, Selleslag D, et al.: Phase II-III study of gemtuzumab ozogamicin monotherapy versus best supportive care in older patients with newly diagnosed AML unfit for intensive chemotherapy: first results of the EORTC-GIMEMA AML-19 trial. [Abstract] Blood 112 (11): A-762, 2008.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):